Clinical Trial

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

Study acronym: NP07
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the safety and efficacy of study drug LY4065967 for the treatment of diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-12-09; most recent amendment 2026-07-03.
Status change: Not Yet Recruiting → Recruiting 2026-01-08
Trial Details
NCT Number NCT07285018
Lead Sponsor Eli Lilly and Company
Conditions Diabetic Peripheral Neuropathic Pain
Enrollment 150 participants
Start Date 2026-02-16
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-07